xanthine oxidase

Xanthine oxidase-IN-10 (XO8 analog) is an inhibitor of xanthine oxidase (XO) used in gout research.

Xanthine oxidase-IN-15 (Compound 6c) is a selective inhibitor of Xanthine oxidase (XO) with an IC50 of 0.13 μM. It inhibits XO by forming stable interactions at the enzyme's active site. Xanthine oxidase-IN-15 is primarily utilized in research related to hyperuricemia and gout.

Xanthine oxidase-IN-17 is a potent xanthine oxidase (XOD) inhibitor with an IC50 of 298 nM and a Ki of 167 nM. By inhibiting the catalytic activity of XOD, it reduces uric acid production and subsequently decreases the formation of O₂⁻ free radicals. Xanthine oxidase-IN-17 is non-cytotoxic in AML-12 liver cells while effectively inhibiting uric acid formation. It is suitable for research on hyperuricemia and gout.

Xanthine oxidase-IN-18 is a potent orally bioavailable xanthine oxidase (XO) inhibitor with an IC50 of 0.263 μM. It exerts its inhibitory effects by directly and stably binding to the Mo-co active site of xanthine oxidase. Xanthine oxidase-IN-18 also possesses reactive oxygen species (ROS) scavenging capabilities. In a potassium oxonate-induced hyperuricemia rat model, it exhibits antihyperuricemic effects. This compound is applicable in research related to hyperuricemia, breast cancer, and lung cancer.

Xanthine oxidase-IN-21, a Genipin derivative, is an orally effective mixed competitive inhibitor of xanthine oxidase (XOD) with an IC50 of 0.68 μM. It alleviates renal fibrosis by reducing α-SMA expression and modulates the NF-κB pathway to inhibit pro-inflammatory cytokines IL-1β, IL-6, and TNF-α. Additionally, Xanthine oxidase-IN-21 suppresses the expression of URAT1 and GLUT9, promoting uric acid excretion and lowering serum uric acid levels. This compound exhibits significant hepatorenal protective effects and can be used in research on hyperuricemia.

Xanthine oxidase-IN-20 is a potent and orally active xanthine oxidase (XO) inhibitor, with an IC50 of 1.7 nM. In mouse and rat models of acute hyperuricemia, it significantly reduces serum uric acid (SUA) levels. Xanthine oxidase-IN-20 exhibits good safety and is applicable in research on hyperuricemia and gout.

Xanthine oxidase-IN-7 (compound 1h) is a potent, orally active xanthine oxidase (XO) inhibitor with an IC50 of 0.36 μM, effectively reducing serum uric acid levels and showing potential for hyperuricemia and gout research [1].

Xanthine oxidase-IN-4 (compound 19a) is an orally active and potent xanthine oxidase (XO) inhibitor with an IC50 of 0.039 μM, suitable for research in hyperuricemia and gout. Xanthine oxidase-IN-4 demonstrates hypouricemic potency in potassium oxonate-induced hyperuricemia rats. [1].

Xanthine oxidase-IN-5, a powerful and orally active inhibitor of xanthine oxidase (XO), exhibits an IC50 value of 0.70 μM. It possesses favorable drug-like characteristics, with ligand efficiency (LE) and lipophilic ligand efficiency (LLE) values of 0.33 and 3.41, respectively. Moreover, Xanthine oxidase-IN-5 showcases significant hypouricemic effects in a hyperuricemic rat model [1].

Xanthine oxidase-IN-6, a potent and orally active mixed-type inhibitor of xanthine oxidase (XOD), demonstrates significant anti-hyperuricemia and renal protective activity with an IC50 value of 1.37 µM.

Xanthine oxidase-IN-8 (Icarisids J) (Compound 7) acts as an inhibitor of xanthine oxidase with an inhibitory concentration (IC50) of 29.71 μM [1].

Xanthine Oxidase-IN-9 (also known as Icarisids E or Compound 2) effectively inhibits xanthine oxidase (XOD) with an IC50 value of 31.81 μM [1].

Xanthine Oxidase-IN-11, an analog of XO8, is an inhibitor of xanthine oxidase (XO) [1].

Xanthine oxidase-IN-12 (Compound 11), an inhibitor of xanthine oxidase (XO), has an IC50 value of 91 nM and exhibits antioxidant properties, also reducing intracellular reactive oxygen species (ROS) [1].

Xanthine oxidase (XO) is an enzyme involved in purine catabolism and conversion to uric acid, generating reactive oxygen species, used in the study of cardiovascular diseases.

Xanthine oxidase-IN-1 is an effective inhibitor of xanthine oxidase with an IC50 value of 6.5 nM. It plays a central role in purine catabolism through the degradation of bioactive nucleotides facilitated by nucleic acid and nucleotide intermediates.

Xanthine oxidase-IN-16 is an effective orally active inhibitor of xanthine oxidase (XO), demonstrating significant therapeutic efficacy in rats with hyperuricemia and an IC50 of 102 nM.

Xanthine oxidase-IN-13 (Compound 10) is a selective inhibitor of xanthine oxidase, with an IC50 of 149.56 μM for bovine xanthine oxidase. It is utilized in the study of inflammatory arthritis.

Tigulixostat (LC350189) is a novel xanthine oxidase inhibitor (XOI) that reduces uric acid production and may be used in studies of gout-related diseases.

Luvadaxistat (TAK-831) is an orally active, potent and highly selective inhibitor of D-amino acid oxidase (DAAO) with an IC50 value of 14 nM for the oxidative deamination of D-serine.Luvadaxistat is used in the study of schizophrenia and cognitive disorders.

Allopurinol (Zyloric) is a Xanthine Oxidase Inhibitor. The mechanism of action of allopurinol is as a Xanthine Oxidase Inhibitor.

Febuxostat (TEI 6720) is a xanthine oxidase inhibitor.

Benzbromarone (Desuric) is a CYP2C9 inhibitor with Ki value of 19.3 nM.

Phytic acid dodecasodium salt hydrate (myo-Inositol, hexakis(dihydrogen phosphate) dodecasodium salt hydrate) is a phosphorus storage compound of seeds and cereal grains. Phytic acid dodecasodium salt hydrate inhibits the enzymatic superoxide source xanthine oxidase with an IC50 of 6 mM and has antioxidative, neuroprotective, and anti-inflammatory effects.